NCT06548932View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerance, PK and PD Parameters of GZR33 and GZR101 in Healthy Male Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

June 30, 2022

Primary Completion Date

February 24, 2023

Study Completion Date

February 24, 2023

Conditions
Healthy Subjects
Interventions
DRUG

GZR33 Injection

A single dose

DRUG

GZR101 Injection

A single dose

DRUG

Placebo

A single dose

Trial Locations (1)

Unknown

Study Site 01, Tianjin

Sponsors
All Listed Sponsors
lead

Gan and Lee Pharmaceuticals, USA

INDUSTRY